Tag: PHA HEA MTC BIO

Pediatric Relapsed/Refractory Neuroblastoma Market is on an Upward Trend, Driven by Innovation and Unmet Need | DelveInsight

The outlook for the neuroblastoma treatment market is optimistic, fueled by progress in targeted therapies and immunotherapies. GD2-targeted immunotherapy is increasingly being incorporated into...

Pediatric Relapsed/Refractory Neuroblastoma Market is on an Upward Trend, Driven by Innovation and Unmet Need | DelveInsight

The outlook for the neuroblastoma treatment market is optimistic, fueled by progress in targeted therapies and immunotherapies. GD2-targeted immunotherapy is increasingly being incorporated into...

Osteosarcoma Market on the Rise in the 7MM During the Forecast Period (2025-2034) with Novel Therapeutics and Technological Innovations | DelveInsight

The dynamics of the osteosarcoma market are anticipated to change due to the extensive R&D activities, entry of novel potential therapies such as HALMB-0168...

Osteosarcoma Market on the Rise in the 7MM During the Forecast Period (2025-2034) with Novel Therapeutics and Technological Innovations | DelveInsight

The dynamics of the osteosarcoma market are anticipated to change due to the extensive R&D activities, entry of novel potential therapies such as HALMB-0168...

ROR Inhibitors Market Expected to Witness Significant Growth Through 2034 Due to the Rising Oncology Research and Pipeline Advancements | DelveInsight

The ROR inhibitors market is witnessing steady growth driven by the increasing understanding of receptor tyrosine kinase-like orphan receptor (ROR) pathways in cancer and...

Precision Era to Redefine Treatment, Drive $450B Economic Investment and Change Lives Across Asia Pacific

SINGAPORE, July 22, 2025 /PRNewswire/ -- The Precision Era of medicine is arriving in Asia Pacific, driven by the arrival of a critical mass...

VivaVision Announces Positive Comments from FDA for the Type C Meeting Regarding VVN461LD for Post-operative Infalmmation – Agreeing the Phase 2 Trial to Be...

HONG KONG and WENZHOU, China, June 9, 2025 /PRNewswire/ -- VivaVision Biotech (VivaVision), a late clinical-stage, privately-held biotech company focused on developing innovative ophthalmic drugs,...

Ascletis Announces Poster Presentations on the Study Results of ASC30 and ASC47 at the 85th Scientific Sessions of American Diabetes Association (ADA)

HONG KONG, June 8, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that poster presentations on preliminary studies of its oral small...

NEFECON®: New Results at ERA 2025 Demonstrate Treatment Benefit of the ‘Treat Early’ Strategy

Two new studies on NEFECON® demonstrate its treatment benefit in the "Treat Early" strategy for IgA nephropathy (IgAN), providing robust support for the new disease...

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Company Name

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Phone

This field is for validation purposes and should be left unchanged.

HomeTagsPHA HEA MTC BIO

Hikvision Releases 2026 Cybersecurity White Paper, Fostering Digital Trust in the AIoT Era

12 Press Releases You Need to See This Week

PAM Health announces plans to open 42-bed medical rehabilitation hospital in West Columbia, South Carolina

Tag: PHA HEA MTC BIO

Pediatric Relapsed/Refractory Neuroblastoma Market is on an Upward Trend, Driven by Innovation and Unmet Need | DelveInsight

Pediatric Relapsed/Refractory Neuroblastoma Market is on an Upward Trend, Driven by Innovation and Unmet Need | DelveInsight

Osteosarcoma Market on the Rise in the 7MM During the Forecast Period (2025-2034) with Novel Therapeutics and Technological Innovations | DelveInsight

Osteosarcoma Market on the Rise in the 7MM During the Forecast Period (2025-2034) with Novel Therapeutics and Technological Innovations | DelveInsight

ROR Inhibitors Market Expected to Witness Significant Growth Through 2034 Due to the Rising Oncology Research and Pipeline Advancements | DelveInsight

Precision Era to Redefine Treatment, Drive $450B Economic Investment and Change Lives Across Asia Pacific

VivaVision Announces Positive Comments from FDA for the Type C Meeting Regarding VVN461LD for Post-operative Infalmmation – Agreeing the Phase 2 Trial to Be...

Ascletis Announces Poster Presentations on the Study Results of ASC30 and ASC47 at the 85th Scientific Sessions of American Diabetes Association (ADA)

NEFECON®: New Results at ERA 2025 Demonstrate Treatment Benefit of the ‘Treat Early’ Strategy

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us